Comparative effectiveness of therapeutic modalities in X-linked hypophosphatemia

X连锁低磷血症治疗方式的疗效比较

• 批准号: 8788783
• 负责人: Eva S. Liu
• 金额: $ 6.58万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8788783
• 关键词: 1,25 (OH) vitamin D; Adverse effects; Affect; Antibodies; Apoptosis; Attenuated; Blocking Antibodies; Blood Vessels; Bone Density; Bone Diseases; Child; Chondrocytes; Chronic; Chronic Kidney Failure; Defect; Dihydroxycholecalciferols; Dose; Early treatment; Epiphysial cartilage; Excretory function; Femur; Functional disorder; Goals; Growth; Homeostasis; Hormones; Hypophosphatemia; Immunohistochemistry; In Situ Hybridization; Inherited; Intervention; Ions; Kidney; Knockout Mice; Laboratories; Length; Life; Link; MAPK3 gene; Measurement; Measures; Mediating; Minerals; Modality; Modeling; Molecular; Morphology; Mus; Nephrocalcinosis; Pathology; Patients; Phenotype; Phosphorylation; Production; Recommendation; Regimen; Relative (related person); Renal function; Reporting; Resistance; Rickets; Role; Serum; Signal Transduction; Staining method; Stains; Supplementation; Therapeutic; Time; Treatment Efficacy; Treatment Protocols; Vitamin D; Weight; alternative treatment; base; comparative effectiveness; comparative efficacy; gastrointestinal; improved; inhibitor/antagonist; inorganic phosphate; mRNA Expression; mineralization; mouse model; novel; parathyroid hormone-related protein; postnatal; prevent; public health relevance; response; skeletal; skeletal abnormality; tibia; treatment strategy; urinary

DESCRIPTION (provided by applicant): X-linked hypophosphatemia (XLH) is characterized by elevated FGF23 levels, which leads to hypophosphatemia and decreased 1,25-dihydroxyvitamin D production. The current treatment includes daily supplementation with phosphate and 1,25-dihydroxyvitamin D, which are not well tolerated and do not uniformly prevent rickets. We aim to compare the ability of chronic low dose or intermittent high dose 1,25-dihydroxyvitamin D or FGF23 blocking antibodies to normalize mineral ions, modulate mineral regulatory hormones, and prevent rickets in hyp mice (murine model of XLH). We have previously shown that hypophosphatemia impairs hypertrophic chondrocyte apoptosis and leads to rickets. Unlike hyp mice, hypophosphatemic Npt2a null mice with elevated 1,25-dihydroxyvitamin D levels have normal growth plates. Our preliminary results demonstrate that treatment of hypertrophic chondrocytes with 1,25-dihydroxyvitamin D induces basal and phosphate-induced ERK1/2 phosphorylation, which is required for phosphate-mediated hypertrophic chondrocyte apoptosis. These studies suggest a role for 1,25-dihydroxyvitamin D in preventing impaired hypertrophic chondrocyte apoptosis in hypophosphatemic states. We hypothesize that treatment with 1,25-dihydroxyvitamin D will attenuate hypophosphatemia and promote hypertrophic chondrocyte apoptosis. Administration of anti-FGF23 antibodies will improve 1,25- dihydroxyvitamin D production and decrease urinary phosphate excretion, thereby increasing serum phosphate and promoting growth plate maturation. Studies with PTHrP null mice have shown PTH/PTHrP to be an inhibitor of growth plate maturation. Moreover, the growth plates in hyp mice have elevated PTHrP expression. We have demonstrated that treatment of hypertrophic chondrocytes with PTH inhibits ERK1/2 phosphorylation in response to phosphate. All three treatment strategies that we propose should decrease PTH/PTHrP levels by increasing 1,25-dihydroxyvitamin D. In particular, intermittent high dosing of 1,25-dihydroxyvitamin D has been shown to effectively suppress PTH levels. We hypothesize that this decrease in PTH/PTHrP may directly and indirectly improve hypertrophic chondrocyte apoptosis by increasing p-ERK1/2 and phosphate. In specific aim 1, we will compare the ability of chronic low dose or intermittent high dose 1,25-dihydroxyvitamin D or anti-FGF23 antibodies to attenuate mineral ion abnormalities and promote growth in hyp mice. Bone mineral density will be evaluated to examine the effects of these three treatments on mineralization. We also propose to compare the efficacy of the three treatments and identify the molecular basis for the improvement of the growth plate phenotype through histological, in situ hybridization, and immunohistochemical analyses.

描述(由申请人提供)：X-连锁低磷血症(XLH)的特征是FGF23水平升高，导致低磷血症和1，25-二羟基维生素D生成减少。目前的治疗方法包括每天补充磷酸盐和1，25-二羟基维生素D，这两种药物的耐受性不好，也不能统一预防软骨病。我们的目标是比较慢性低剂量或间歇高剂量1，25-二羟基维生素D或FGF23阻断抗体在Hyp小鼠(XLH小鼠模型)中正常化矿物质离子、调节矿物质调节激素和预防软骨病的能力。我们先前已经证明，低磷血症会损害肥大的软骨细胞的凋亡，并导致软骨病。与Hyp小鼠不同，1，25-二羟基维生素D水平升高的低磷Npt2a缺失小鼠生长板正常。我们的初步结果表明，1，25-二羟基维生素D处理肥大软骨细胞诱导基础和磷酸盐诱导的ERK1/2磷酸化，这是磷酸盐介导的肥大软骨细胞凋亡所必需的。这些研究表明，1，25-二羟基维生素D在防止低磷状态下受损的肥大软骨细胞凋亡方面具有作用。我们推测，用1，25-二羟基维生素D治疗可以减轻低磷血症，促进肥大软骨细胞的凋亡。给予抗FGF23抗体将增加1，25-二羟基维生素D的产生，减少尿磷排泄，从而增加血清磷，促进生长板成熟。对PTHrP缺失小鼠的研究表明，PTH/PTHrP是生长板成熟的抑制因子。此外，Hyp小鼠的生长板有升高的PTHrP表达。我们已经证明，用甲状旁腺素处理肥大的软骨细胞会抑制ERK1/2的磷酸化，以回应磷酸盐。我们提出的所有三种治疗策略都应该通过增加1，25-二羟基维生素D来降低PTH/PTHrP水平。特别是，间歇性高剂量的1，25-二羟基维生素D已被证明有效地降低了PTH水平。我们推测，PTH/PTHrP的这种降低可能通过增加p-ERK1/2和磷酸盐，直接或间接地改善肥大软骨细胞的凋亡。在具体目标1中，我们将比较慢性低剂量或间歇性高剂量1，25-二羟基维生素D或抗FGF23抗体减轻Hyp小鼠矿物质离子异常和促进生长的能力。将评估骨密度，以检查这三种处理方法对矿化的影响。我们还建议通过组织学、原位杂交和免疫组织化学分析比较三种治疗方法的疗效，并确定改善生长板表型的分子基础。